FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a pharmaceutical preparation containing an agent that blocks EPI-activity (inhibitor) as an active component and benefit preparation for treatment of patients with prolonged coagulation time. Invention relates to also a method of acceleration of blood coagulation in vitro using the claimed preparation and the use of an inhibitor of EPI-activity as a substance that is able to accelerate blood coagulation process. Preparation shows a tendency to decrease bleeding in patients. EFFECT: enhanced effectiveness of a preparation proposed. 7 cl, 4 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED FACTOR VII | 1995 |
|
RU2214833C2 |
| APPLICATION OF FVIIa OR TISSUE FACTOR ANTAGONIST TO REGULATE GENE EXPRESSION AND CELL JOURNEY OR CHEMOTAXIS | 2000 |
|
RU2268744C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING FACTOR VII POLYPEPTIDES AND FACTOR XI POLYPEPTIDES | 2002 |
|
RU2298416C2 |
| INTEGRAL APPLICATION OF FACTOR VII POLYPEPTIDES AND FACTOR IX POLYPEPTIDES | 2002 |
|
RU2292909C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VII POLYPEPTIDES AND PAI-1 POLYPEPTIDES | 2002 |
|
RU2304980C2 |
| ANTIBODIES AGAINST INHIBITOR OF TISSUE FACTOR METABOLIC PATHWAY | 2009 |
|
RU2562114C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VIIA AND FACTOR XIII | 2001 |
|
RU2272648C2 |
| COMBINED APPLICATION OF FACTOR VII POLYPEPTIDES AND FACTOR VIII POLYPEPTIDES | 2002 |
|
RU2311923C2 |
| FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS | 2011 |
|
RU2606155C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
